Work

Considerations for lifetime management of aortic stenosis: Transcatheter aortic valve replacement, surgical aortic valve replacement, and timing of therapy

Year: 2024

Type: article

Abstract: Severe aortic valve stenosis (AS) is the primary reason for heart valve intervention in Europe and the United States,1 affecting 52.5 individuals (95% confidence interval [CI], 49.4-55.8) per 100,000 patient-years.2 The management of AS has evolved dramatically in recent years driven by advancements in treatment modalities and a deeper understanding of disease progression and its impact on survival and quality of life. While elderly, frail patients with a high burden of comorbidities were previously considered inoperable or at high surgical risk for surgical aortic valve replacement (SAVR), the landscape of AS management has been revolutionized by the introduction of transcatheter aortic valve replacement (TAVR).

Source: JTCVS structural and endovascular.

DOI: 10.1016/j.xjse.2024.100028

Authors: Rodrigo Petersen Saadi, Ana Paula Tagliari, Syed Zaid, Gilbert H.L. Tang

Institutions: Universidade Federal do Rio Grande do Sul, Hospital Mãe de Deus, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Mount Sinai Health System

Language: English

Topic: Cardiac Valve Diseases and Treatments

Subfield: Cardiology and Cardiovascular Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,500